

Certificate of Analysis

p27 complex, activated

(Recombinant protein expressed in Sf21 insect cells)

Item # 23-024, 23-024-K, 23-024M

Parent Lot # D11DP017N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: Complex of *N*-terminal c-Myc-tagged, recombinant human p27 full length, 6His-tagged, recombinant human Cyclin E1 full length and untagged, recombinant human CDK2 full length, co-expressed by baculovirus in Sf21 insect cells. Purified using immobilized metal affinity chromatography. Phosphorylated *in vitro* using CDK2/Cyclin E1.

Purity 94.6% by SDS-PAGE and Coomassie blue staining. p27 MW = 23kDa, CDK2 MW = 34kDa, Cyclin E1 MW = 48kDa

Formulation: 0.444mg/ml of enzyme in 25mM MOPS pH7.5, 5mM MgCl₂, 0.01% Tween 20, 1mM ATP. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.



Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS

Quality Control Testing

Assay: This enzyme was titrated in a ubiquitination assay and the results normalised against the maximum signal.

Protein Identity: Confirmed identity as p27, CDK2 and Cyclin E1 by mass spectrometry.



Certificate of Analysis

Assay Protocol

Reagents:

- | | |
|---|---------------------------|
| 1. UBE1, active (Item # 23-021) | 4. 1x Reaction Buffer |
| 2. UbchH3, active (Item # 23-022) | 5. Biotinylated-Ubiquitin |
| 3. SCF ^{Skp2/Cks1} complex, active (Item # 23-023) | 6. Stop Solution |

Assay Outline:

All enzymes and reagents are diluted in the 1x reaction buffer (25mM MOPS pH7.5, 0.01% Tween 20, 5mM MgCl₂).

p27 complex, activated is incubated with 25mM MOPS pH7.5, 0.01% Tween 20, 5mM MgCl₂, 10μM ATP, 10nM UBE1, 500nM UbchH3, 5ug/ml SCF^{Skp2/Cks1} complex and 2μM biotinylated-ubiquitin. The reaction is initiated with the addition of biotinylated-ubiquitin. After 30 minutes at room temperature the reaction is terminated by the addition of 25mM MOPS pH7.5 containing 125mM EDTA, 150mM NaCl and 0.05% Tween 20. Reaction products are separated by capture onto a microplate coated with anti-c-Myc antibody and washing with PBS containing 0.05% Tween 20. Ubiquitination of p27 complex is measured by detection of bound ubiquitin via electrochemiluminescence.

p27 Complex Information

<u>Protein</u>	human p27, human CDK2, human Cyclin E1
<u>Accession number</u>	GenBank BC001971 p27, GenBank NM_001798 CDK2, GenBank NM_001238 Cyclin E1
<u>Alternative Names</u>	p27 ^{Kip1} , Kip1, Cyclin-dependent kinase inhibitor 1B
<u>Key Facts</u>	p27 is an important regulator of cell cycle progression, involved in G1 arrest. It is a potent inhibitor of cyclin E1- and cyclin A-CDK2 complexes and a positive regulator of cyclin D-dependent kinases such as CDK4. The degradation of this protein, which is triggered by its CDK-dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Decreased levels of p27 are found in various epithelial tumours originating from lung, breast, colon, ovary, oesophagus, thyroid and prostate. Defects in the gene encoding p27 (CDKN1B) are the cause of multiple endocrine neoplasia type 4 (MEN4) an inherited cancer of the thyroid.
<u>Related Products</u>	Item # 23-021 UBE1, active, Item # 23-022 UbchH3, active, Item # 23-023 SCF ^{Skp2/Cks1} complex, active

Selected References

- Besson A. *et al.* Discovery of an Oncogenic Activity in p27^{Kip1} that Causes Stem Cell Expansion and a Multiple Tumor Phenotype. *Genes Dev.*, 21: 1731-1746, 2007
- Grimmler M. *et al.* Cdk-Inhibitory Activity and Stability of p27^{Kip1} are Directly Regulated by Oncogenic Tyrosine Kinases. *Cell*, 128: 269-280, 2007
- Lee J. and Kim S. S. The Function of p27^{Kip1} During Tumor Development. *Exp Mol Med.* 41: 765–771, 2009
- Ungermannova D. *et al.* Ubiquitination of p27^{Kip1} Requires Physical Interaction with Cyclin E and Probable Phosphate Recognition by SKP2. *J. Biol. Chem.*, 280: 30301–30309, 2005
- Pellegata N. S. *et al.* Germ-line Mutations in p27^{Kip1} Cause a Multiple Endocrine Neoplasia Syndrome in Rats and Humans. *PNAS*, 103: 15558-15563, 2006

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services